Advertisement

Immune tolerance to Factor VIII:The international registry data

  • G. Mariani
  • M. Hilgartner
  • A. R. Thompson
  • J. Tusell
  • M. Manco-Johnson
  • A. Ghirardini
  • R. Bellocco
  • H. H. Brackmann
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 386)

Abstract

Among the problems related to the treatment of classic hemophilia, the presence of inhibitors (alloantibodies) to foreign Factor VIII (F.VIII) is one of the most serious. These antibodies may arise at any age, but the cumulative risk of developing an inhibitor one year after the first treatment with a factor concentrate is between 22% and 25%. 1,2The presence of such antibodies can render any further administration of F.VIII ineffective. On the basis of the speed and degree of immune response to F.VIII, patients have been divided into high- and low-responders.3This is an arbitrary classification, but it is related to important treatment characteristics. Low responders, that is patients whose maximum inhibitor titer is <10 Bethesda Units (B.U.), can be treated with F.VIII, albeit at higher doses; however, high-responders can seldom be treated with F.VIII and comprise the so-called “refractory hemophiliacs.”

Keywords

Factor VIII Coagulation Factor Immune Tolerance Recombinant Factor VIII Factor Viii Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. Ehrenforth, W. Kreuz, I. Sharrer, R. Linde, M. Funk, T. Gungor, B. Krackhardt, and B. Kornhuber, Incidence of development of factor VIII and factor IX inhibitors in hemophiliacs, Lancet 339:594 (1992).PubMedCrossRefGoogle Scholar
  2. 2.
    J.M. Lusher, S. Arkin, C.F. Abilgaard, R.S. Schwartz and the Kogenate Previously Untreated Patient Study Group, Recombinant Factor VIII for the treatment of previously untreated patients with hemophilia A, N. Engl. J. Med. 328:453 (1993).Google Scholar
  3. 3.
    J. P. Allain, D. Frommel, Antibodies to factor VIII. V. Patterns of immuneresponse to factor VIII in hemophilia A, Blood 47:973 (1976).PubMedGoogle Scholar
  4. 4.
    H. H. Brackmann, J. Gormsen, Massive factor-Vlriinfusion in hemophiliac with factor VIII inhibitor, high responder, Lancet 2:933 (1977).PubMedCrossRefGoogle Scholar
  5. 5.
    H.H. Brackmann, Induced immune tolerance in factor VIII inhibitor patients, Progr Clin Biol Res 150:181 (1984).Google Scholar
  6. 6.
    G.C. White, R.E. Taylor, P.M. Blatt, H.R. Roberts, Treatment of a high-titre anti-factor VIII antibody for continuous factor VIII administration:Report of a case, Blood 62:141 (1983).PubMedGoogle Scholar
  7. 7.
    J.A. Aznar, J.J. Jorquera, A. Peiro, I. Garcia, The importance of corticoids added to continuous treatment with factor VIII concentrates in the suppression of inhibitors in haemophilia A, Thromb Haemost 51:217 (1984).PubMedGoogle Scholar
  8. 8.
    S. Stenbjerg, J. Ingerslev, E. Zacharie, Factor VIII inhibitor treatment with high doses of FVIII, Thromb Res 34:533 (1984).PubMedCrossRefGoogle Scholar
  9. 9.
    E. Scheibel, C. Feddersen, H. Hertz, Long-term high dose factor VIII treatment of 3 hemophiliacs with factor VIII inhibitor, Scand J Haematol 34:378 (1985).PubMedCrossRefGoogle Scholar
  10. 10.
    E. F. van Leewen, E.P. Mauser-Bunschoten, RJ. van Dijken, A. J. Kok, E.J.M. Sjamsedin-Visset, J.J. Sixma, Disappearance of factor VIILC antibodies in patients with hemophilia A upon frequent administration of factor VIII in intermediate or low dose, Br J Haematol 64:291 (1986).CrossRefGoogle Scholar
  11. U.E. Scheibel, J. Ingerslev, J. Dalsgaard-Nielsen, S. Stenbjerg, J. B. Knudsen and the Danish Study Group, Continuous high-dose factor VIII for the induction of immune tolerance in haemophilia A patients with high responder state:A description of eleven patients treated, Thromb Haemost 58:1049 (1987).Google Scholar
  12. 12.
    N. Ewing, N.L. Sanders, S. L. Dietrich, C. K. Kasper, Induction of immune tolerance to Factor VIII in hemophiliacs, JAMA 259:65 (1988).PubMedCrossRefGoogle Scholar
  13. 13.
    R.A. Gruppo, Immunetolerance induction with once weekly factor VIH infusions in patients with hemophilia A and inhibitors, Thromb Haemost 65:1168 (1991) (abstract).Google Scholar
  14. 14.
    G. Mariani, S. Solinas, D. Pasqualetti, A. Ghirardini, P. Verani, S. Butto, M. Lopez, T. Moretti, Induction of Immunetolerance in hemophilia for high titre inhibitor eradication:A long term follow-up, Thromb Haemost 62:835 (1989).PubMedGoogle Scholar
  15. 15.
    C.K. Kasper, LM. Aledort, R.B. Counts, J.R. Edson, J. Fratantoni, D. Green, J.W. Hampton, M. W. Hilgartner, J. Lazeson, P.H. Levine, C.W. McMillan, J. Pool, S.S. Shapiro, N.R. Shulman, J. Van Eye, A more uniform measurement of factor VIII inhibitors, Thromb Diath Haemorrh 34:875 (1975).PubMedGoogle Scholar
  16. 16.
    A.G. Dean, J.A. Dean, A.H. Burton, R.C. Dicker, Epi Info, version 5:A word processing, database and statistics program for epidemiology on microcomputers. USD Inc., Stone Mountain, GA, 1990.Google Scholar
  17. 17.
    W.J. Dixon, 1985, “BMPD statistical software,” University of California Press, Berkeley, CA.Google Scholar
  18. 18.
    J.L. Fleiss, 1973, “Statistical methods for rates and proportions,” John Wiley & Sons, Inc., New York, NY.Google Scholar
  19. 19.
    I.M. Nilsson, E. Berntorp, O. Zettervall, Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII, N Engl J Med 318:947 (1988).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • G. Mariani
  • M. Hilgartner
  • A. R. Thompson
  • J. Tusell
  • M. Manco-Johnson
  • A. Ghirardini
  • R. Bellocco
  • H. H. Brackmann

There are no affiliations available

Personalised recommendations